Key Highlights
- Calidi Biotherapeutics shares fell approximately 18%.
- The company disclosed a 1-for-16 reverse stock split scheduled to take effect on July 31, 2026.
- The company will continue trading under its current ticker.
- All outstanding warrants, options, and convertible instruments will undergo proportional adjustments.
Calidi Biotherapeutics (NYSE: CLDI) shares fell approximately 18% after the company disclosed a 1-for-16 reverse stock split scheduled to take effect on July 31, 2026.
What Happened
The company said it will continue trading under its current ticker while consolidating equity to bolster investor interest.
All outstanding warrants, options, and convertible instruments will undergo proportional adjustments following the share consolidation.
Market Reaction
Shares fell approximately 18% following the disclosure, a reaction commonly seen around reverse stock split announcements, which are often associated with efforts to maintain minimum listing price requirements.
Outlook
The 1-for-16 reverse stock split is scheduled to take effect on July 31, 2026, with proportional adjustments applying to all outstanding warrants, options, and convertible instruments.
What did Calidi Biotherapeutics announce?
A 1-for-16 reverse stock split scheduled to take effect on July 31, 2026.
Will Calidi Biotherapeutics change its ticker symbol?
No, the company will continue trading under its current ticker.
How will the reverse split affect warrants and options?
All outstanding warrants, options, and convertible instruments will undergo proportional adjustments following the share consolidation.






Please wait processing your request...